Soliris 300 mg (Eculizumab) Injection
Brand: Soliris® | Generic: Eculizumab | Manufacturer: Alexion Prescription-only complement inhibitor biologic. Solaris 300 mg injection price Available to hospitals and specialist treatment centers.
Overview
Soliris (eculizumab) is a complement-inhibitor monoclonal antibody manufactured by Alexion, used in rare, complement-mediated disorders including paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). If you’re researching Soliris 300 mg price in India, note that pricing depends on dosing protocol, order volume, and current supply — institutional buyers can request current rates below.
YourMedikart supplies genuine Soliris 300 mg vials to hospitals, specialist treatment centers, and authorized institutional buyers across India, with sourcing support for eculizumab availability and documentation.
Eculizumab Mechanism of Action
Eculizumab is a humanized monoclonal antibody that binds to complement protein C5, blocking its cleavage into C5a and C5b. This stops formation of the terminal complement complex (C5b-9), which is what damages red blood cells in PNH, drives microvascular clotting in aHUS, and contributes to the immune attack on the neuromuscular junction and central nervous system in gMG and NMOSD respectively. By interrupting this single step in the complement cascade, eculizumab reduces hemolysis and inflammation without broadly suppressing the immune system — though it does leave patients more vulnerable to certain encapsulated bacteria, which is why meningococcal vaccination is required before treatment (see Warnings below).
Approved Soliris Drug Uses
Paroxysmal Nocturnal Hemoglobinuria (PNH) Reduces hemolysis in adults with PNH, which can ease fatigue, dark urine, and anemia, and may reduce transfusion need.
Atypical Hemolytic Uremic Syndrome (aHUS) Used in adults and children ≥5kg to inhibit the abnormal clotting (thrombotic microangiopathy) seen in aHUS and protect organ function. Not indicated for Shiga toxin-producing E. coli HUS (STEC-HUS).
Generalized Myasthenia Gravis (gMG) Used in adults and children 6+ with anti-AChR antibody-positive gMG to improve muscle strength and reduce symptoms like breathing and swallowing difficulty.
Neuromyelitis Optica Spectrum Disorder (NMOSD) Used in AQP4-antibody-positive adult NMOSD to reduce relapse risk and protect against optic nerve/spinal cord damage. Clinical trials showed roughly a 94% reduction in relapses versus placebo over 48 weeks.
Dosing Schedule (institutional reference)
| Phase | Dose | Frequency |
|---|---|---|
| Induction | 600 mg IV infusion | Once weekly × 4 doses |
| Induction (5th dose) | 900 mg IV infusion | 1 week after 4th dose |
| Maintenance | 900 mg IV infusion | Every 14 days thereafter |
Pediatric dosing is weight-based; infusion time is at least 35 minutes for adults and up to 4 hours for children. Full renal/weight-adjusted tables should be sourced from the prescribing label shipped with each order.
Boxed Warning & Key Safety Information
- Life-threatening meningococcal infection risk. Patients must receive meningococcal vaccination at least 2 weeks before the first dose, or receive prophylactic antibiotics if treatment can’t be delayed. Discontinue in patients being treate for active meningococcal infection.
- Increased susceptibility to other serious infections, including Neisseria species and disseminated gonococcal infection.
- Infusion-related reactions can occur; monitor for at least 1 hour post-infusion.
- Administer only as IV infusion — never as IV push or bolus.
- Monitor for hemolysis (PNH) or TMA symptoms (aHUS) for 8–12 weeks after discontinuation.
Common Side Effects
Most frequently reported: headache, fatigue, nausea, diarrhea, muscle/joint pain, and upper respiratory symptoms. Seek immediate medical attention for facial/throat swelling, chest pain, or difficulty breathing during infusion — these can indicate a serious reaction.
Storage
Store refrigerated (2–8°C), do not freeze, protect from light. Diluted product must used within 24 hours.
Sourcing & Ordering
Soliris 300 mg is available to hospitals, specialist centers, and licensed pharmacies through YourMedikart’s institutional supply channel. Submit your institution’s purchase order and prescribing documentation for current Soliris 300 mg price in India and lead times.
[Enquire for Institutional Pricing]
FAQ
What is the mechanism of action of eculizumab?
Eculizumab binds complement protein C5 and blocks formation of the terminal complement complex, preventing the complement-driven cell damage seen in PNH, aHUS, gMG, and NMOSD
What are the main Soliris drug uses?
Soliris is approved for PNH, aHUS, generalized myasthenia gravis (AChR-antibody positive), and NMOSD (AQP4-antibody positive) in adults, with pediatric approval for some indications.
What is the Soliris 300 mg price in India?
Pricing depends on the dosing protocol and order volume. Hospitals and licensed pharmacies can submit a purchase enquiry for current institutional rates.
Is Soliris available as a tablet?
No. Soliris is available only as an IV infusion; there is no tablet formulation.
Why does Soliris require a meningococcal vaccine first?
Because eculizumab blocks part of the complement system that normally helps fight certain bacteria, patients face a higher risk of meningococcal infection. Vaccination at least 2 weeks before the first dose is required unless treatment is urgent.
